MSD Belzutifan PAS

Inclusion Criteria: * Greater than or equal to 18 years of age * Diagnosed with VHL disease based on a germline test or clinical diagnosis * A decision has been made by the treating physician (at his/her discrestion) to intitate the first belzutifan treatment (i.e., belzutifan 'new users'), within the prescribing conditions of the approved product label * Signed informed consent prior to or withing 30 days after the first inititaion of belzutifan Exclusion Criteria: * Anti-cancer systemic therapy within 2 weeks prior to the index date * Unable to consent to participate in the study * History of VHL disease-related metastasis or advanced cancer